Validation of the Mantle Cell Lymphoma International Prognostic Index: A single-center retrospective analysis.
Mantle cell lymphoma (MCL) is a unique, recently recognized entity with a variable clinical course [1]. Its historical grouping as an indolent lymphoma belies its common behavior, which is generally aggressive and incurable, with a median survival of about 5 years with modern therapy [2]. In an effort to improve outcomes in MCL, intensified therapies, including the rituximab plus HyperCVAD regimen [3] and incorporation of hematopoetic progenitor cell transplantation (HPCT) [4-6], have been used. However, although capable of inducing remissions in most patients, there is little proof that intensive first-line therapy prolongs overall survival (OS), and a continual relapse pattern is commonly observed [4,7-10].
Stephen D
SD
Smith
Eric
E
Hsi
Brian
B
Bolwell
Brad
B
Pohlman
Robert
R
Dean
Meagan
M
Effinger
Amanda
A
Maggiotto
John
J
Sweetenham
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D053208:Kaplan-Meier Estimate; D020522:Lymphoma, Mantle-Cell / Q000145:classification* / Q000188:drug therapy / Q000401:mortality / Q000601:surgery; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012189:Retrospective Studies; D000069283:Rituximab; D012720:Severity of Illness Index; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D014750:Vincristine / Q000008:administration & dosage
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide